Form 4: Corcept Therapeutics CEO Joseph Belanoff Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Corcept Therapeutics CEO Joseph K. Belanoff sold shares of common stock on March 31, 2025, and April 1, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- Joseph K. Belanoff, CEO of Corcept Therapeutics, sold shares of the company's common stock on March 31, 2025, and April 1, 2025.
- The sales were executed under a Rule 10b5-1 trading plan adopted on November 26, 2024.
- On March 31, 2025, 35,102 shares were sold at a price of $94.72 per share.
- On April 1, 2025, 350 shares were sold at a price of $114.71 per share.
- Following these transactions, Belanoff indirectly owns 2,981,985 shares through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock sales by an insider. The sales are conducted under a pre-arranged plan, so it doesn't necessarily indicate a negative outlook, but it's also not a positive signal.
Industry Context
Insider sales are a common occurrence, and the use of 10b5-1 plans allows corporate insiders to sell shares in a pre-planned manner to avoid accusations of trading on non-public information. The market typically analyzes the size and frequency of such sales to gauge insider sentiment.
Stakeholder Impact
- Shareholders may interpret the stock sales as a neutral event given the pre-planned nature of the transactions.
- The impact on employees, customers, suppliers, and creditors is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 04/29/02 | Date of the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust |
| 11/26/2024 | Date the Reporting Person adopted the Rule 10b5-1 trading plan |
| 03/31/2025 | Date of the first reported transaction (sale of shares) |
| 04/01/2025 | Date of the second reported transaction (sale of shares) |
| 04/02/2025 | Date of the signature on the Form 4 filing |
Keywords
Form 4, Insider Trading, Stock Sale, Joseph Belanoff, Corcept Therapeutics, CORT, 10b5-1 plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.